(Q79294407)
Statements
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer (English)
L Boerrigter
H Ruijter
I Tielen
D de Jong
P Baas
S Burgers
23 October 2006